// App-Quantinova.ai

: Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials

Researchers

Presenter

  • Joaquim Mullol

Principal Investigators

  • Tanya M. Laidlaw

  • Nikhil Amin

  • Claus Bachert

  • Joseph K. Han

  • Peter W. Hellings

  • G. Walter Canonica

  • Seong H. Cho

  • Jorge F. Maspero

  • Martin Desrosiers

  • Claire Hopkins

  • Pierluigi Paggiaro

  • Mei Zhang

  • Xin Lu

  • Naimish Patel

  • Neil M.H. Graham

  • Heribert Staudinger

  • Leda P. Mannent

Medical Centers

  • Hospital Clinic, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Spain

  • Brigham and Women's Hospital - Boston - United States of America

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

  • Ghent University and CLINTEC, Karolinska Institutet, Ghent (Belgium) and Stockholm, Sweden

  • Eastern Virginia Medical School, Norfolk, United States of America

  • Humanitas Clinical and Research Hospital, Milan, Italy

  • University of South Florida, Tampa, United States of America

  • Fundacion GADOR, Buenos Aires, Argentina

  • Centre de Recherche du Centre Hospitalier de lUniversite de Montreal, Montreal, QC, Canada

  • University of Pavia, Pavia, Italy

  • Sanofi US, Bridgewater, United States of America

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

  • Sanofi, Chilly-Mazarin, France

Locations

  • Spain

  • United States

  • Sweden

  • Belgium

  • Italy

  • Argentina

  • Canada

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02912468

  • NCT02898454

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved